Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244855 · ClinicalTrials.gov registry record · Phase 2
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00244855: Completed Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
NCT00244855 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00244855, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well giving rituximab and dexamethasone together works in treating patients with low-grade non-Hodgkin lymphoma (NHL). Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with dexamethasone may kill more cancer cells
Primary Outcome
Survival without measurable progression of lymphoma estimated according to the Kaplan-Meier method
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL rituximab
- DRUG dexamethasone
- OTHER pharmacological study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-05 |
| Est. Completion | 2011-08-29 |
| Phase | Phase 2 |
What the finished NCT00244855 record still lists
NCT00244855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00244855 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00244855 about?
NCT00244855 is a clinical study titled "Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma". This phase II trial studies the side effects and how well giving rituximab and dexamethasone together works in treating patients with low-grade non-Hodgkin lymphoma (NHL). Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to g...
What is the current status of trial NCT00244855?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2004-05. Estimated completion is 2011-08-29.
What interventions are being tested in trial NCT00244855?
The interventions under investigation include: laboratory biomarker analysis (OTHER), rituximab (BIOLOGICAL), dexamethasone (DRUG), pharmacological study (OTHER).
Who is sponsoring clinical trial NCT00244855?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00244855's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia